Comparative Pharmacology
Head-to-head clinical analysis: BYETTA versus XULTOPHY 100 3 6.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYETTA versus XULTOPHY 100 3 6.
BYETTA vs XULTOPHY 100/3.6
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying, and promotes satiety.
Xultophy 100/3.6 is a combination of insulin degludec (a long-acting basal insulin analog) and liraglutide (a GLP-1 receptor agonist). Insulin degludec binds to insulin receptors, promoting cellular glucose uptake and inhibiting hepatic glucose production. Liraglutide activates GLP-1 receptors, increasing insulin secretion, decreasing glucagon secretion, and slowing gastric emptying.
5 mcg subcutaneously twice daily within 60 minutes before morning and evening meals; may increase to 10 mcg twice daily after 1 month if tolerated.
Subcutaneous injection once daily, starting at 10 units (10 units insulin degludec and 3.6 mcg liraglutide). Titrate by 2 units every 3-4 days based on fasting plasma glucose to a maximum of 50 units daily.
None Documented
None Documented
Terminal elimination half-life 2.4 hours; provides clinical duration of action supporting twice-daily dosing.
Insulin degludec: ~25 hours (range 22-28 hours); liraglutide: ~13 hours. The ultra-long half-life of insulin degludec allows once-daily dosing with flat activity profile.
Primarily renal; intact drug eliminated in urine (approximately 80% of the dose). Minor biliary/fecal excretion accounts for <10%.
Renal: insulin degludec and liraglutide are cleared primarily via degradation, with less than 2% excreted unchanged renally. Fecal: negligible.
Category C
Category C
Antidiabetic
Antidiabetic